
Nora AI teaches scientists how to discover antiviral drugs by focusing on host-cell biology and host-targeted strategies. The offering is an online educational course composed of modular lessons, practical exercises, and case studies designed for researchers and drug discovery teams. It positions itself as an instructional resource for understanding disease mechanisms and identifying host-focused therapeutic candidates. As an educational product, it targets researchers in academia, biotech, and pharmaceutical organizations. Nora AI addresses the growing need for host-directed antiviral approaches in preclinical drug discovery.

Nora AI teaches scientists how to discover antiviral drugs by focusing on host-cell biology and host-targeted strategies. The offering is an online educational course composed of modular lessons, practical exercises, and case studies designed for researchers and drug discovery teams. It positions itself as an instructional resource for understanding disease mechanisms and identifying host-focused therapeutic candidates. As an educational product, it targets researchers in academia, biotech, and pharmaceutical organizations. Nora AI addresses the growing need for host-directed antiviral approaches in preclinical drug discovery.
Core focus: Host-cell-focused antiviral drug discovery
Product: Online educational course (modular lessons, practical exercises, case studies) for researchers and drug-discovery teams
Headquarters: Tallinn, Harjumaa, Estonia
Funding: Angel round announced Dec 21, 2023 — lead investor: Arti Kütt
Industry & team: Biotechnology; team size reported as 1–10
Antiviral drug discovery with emphasis on host-cell biology and host-targeted therapeutic strategies.
Biotechnology
Number of investors reported as 1